The Latin America, Middle East and Africa Cardiac Marker Testing Market would witness market growth of 10.6% CAGR during the forecast period (2022-2028).
Patients with chest pain and suspicion of acute coronary syndrome are diagnosed and risk-stratified using cardiac markers, and cardiac troponin (especially troponin I) is particularly helpful in the diagnosis of myocardial infection because of its higher specificity compared to certain other cardiac markers. Non-ST-segment elevation MI is now the term used to describe people with myocardial infarction symptoms and high troponin I or troponin T but no alterations in their electrocardiogram.
There are now high-sensitivity cardiac troponin assays that can measure troponin readings at significantly lower concentrations. More individuals with unstable angina will be labeled as having non-ST-elevation myocardial infarction due to the use of these high-sensitivity diagnostics. These tests may therefore identify a group of individuals who are at high risk, which could then receive more suitable treatment and have better results.
One aspect of the increase in illnesses is the region's population's aging. The country of South Africa has an estimated population of 56.5 million people, according to Statistics South Africa's most recent mid-year population predictions. Furthermore, South Africa's elderly population—defined as those 60 and older—is increasing and reached 8.1% in 2017. In South Africa, there are 4.6 million people over the age of 60.
The Brazil market dominated the LAMEA Cardiac Marker Testing Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $127.1 million by 2028.The Argentina market is experiencing a CAGR of 11.2% during (2022 - 2028). Additionally, The UAE market would display a CAGR of 10.3% during (2022 - 2028).
Based on Disease, the market is segmented into Myocardial Infarction, Congestive Heart Failure, Atherosclerosis, Acute Coronary Syndrome and Ischemia. Based on End User, the market is segmented into Laboratory Testing Facilities, Point-of-Care Testing Facilities and Academic Institutions. Based on Product, the market is segmented into Reagents & Kits and Instruments. Based on Biomarker Type, the market is segmented into Troponin I & T, Creatine kinase-MB(CK-MB), Natriuretic peptide (Bnp Or Nt-Probnp), Myoglobin, High-sensitivity C-reactive protein(hs-CRP) and Others. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
Free Valuable Insights: The Global Cardiac Marker Testing Market is Predict to reach $8.1 Billion by 2028, at a CAGR of 8.3%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include F. Hoffmann-La Roche Ltd., Abbott Laboratories, Danaher Corporation, Siemens Healthineers AG (Siemens AG), PerkinElmer, Inc., BioMérieux S.A., Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., Thermo Fisher Scientific, Inc., and DiaSorin S.p.A.
By Disease
By End User
By Product
By Biomarker Type
By Country
Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
Unique Offerings 